Search
Streptococcus pneumoniae type 11a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10330ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheCX501
go.drugbank.com/drugs/DB05174InvestigationalIt is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of
Kappadione
go.drugbank.com/drugs/DB09332ApprovedIt has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544]. … not available in North America [L1543].
Quinidine barbiturate
go.drugbank.com/drugs/DB01346ApprovedA papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909)
Products: NATISEDINE 100 MG TABLET, 20 ADETResmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalOn March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … [L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD.
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigationalCurrently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due … [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigationalIt is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Nogapendekin alfa, in combination with inbakicept, mimics the actions of IL-15, , stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which
Lutein
go.drugbank.com/drugs/DB00137ApprovedNutraceuticalIn green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very … Lutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots.
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnLevopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. … [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalIt inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. … It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea.
Synonyms: N-(n-Butyl)deoxynojirimycin, N-ButylmoranolineProducts: ZAVESCA® 100 MG, Miglustat G.L. 100 mg-Hartkapseln